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THE secretory leukocyte protease inhibitor (SLPI) is a
low-molecular-weight inhibitor of proteases, such as
elastase  and  cathepsin  G  which  are  released  from
leukocytes during phagocytosis. The purpose of this
study was to determine whether or not SLPI is able to
inhibit IgE-mediated histamine release. Nasal mucosa
from 11 test subjects without atopic disposition was
used  for  this  in  vitro study.  We  found  that  SLPI
inhibited histamine release in a dose-dependent way
but  was  without  influence  on  the  spontaneous
release.
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Introduction
Secretory leukocyte protease inhibitor (SLPI) is a non-
glycosylated, acid-stable, neutral  serine antiprotease
first described by Haendle et al. in 1965.1 Isolation of
native inhibitor (SLPI) from parotide juice allowed the
determination of its amino acid sequence.2 SLPI is an
important regulator of proteases such as granulocyte
elastase and cathepsin G. It prevents these enzymes
from inhibiting the mucociliary activity in the airways
during  purulent  infection.3–7 It  is  found  in  great
amounts in nasal secretion and is thought to be the
major  inhibitor  of  granulocyte  elastase  in  these
secretions, while a 1-PI plays a minor role.8,9
Mast cells initiate hypersensitive reactions by bind-
ing  IgE  to  high-affinity  receptors  within  the  cell
membrane  in  response  to  allergen  challenge. This
response causes a rapid release of several mediators,
such as histamine and proteases.10,11 SLPI has been
found  to  inhibit  one  of  these  enzymes,  namely
chymase.12,13 It  has  been  found  to  be  the  fastest
reacting  chymase  inhibitor  compared  with  plasma
inhibitors such as a 1-PI and a 1-antichymotrypsin.14
Chymase is thought to play an important role in IgE-
mediated  histamine  release  by  causing  mast  cell
degranulation.15–17 Inhibitors of chymase have been
shown to inhibit IgE-mediated histamine release from
isolated mast cells, probably after incorporation into
mast cell granules. This implies that chymase may play
a role in the stimulation of the IgE-mediated activa-
tion/secretion response.18,19 It has also been demon-
strated that  SLPI  increases  in nasal secretion when
patients  with  atopic  disposition  are  exposed  to
allergen  and  histamine.20 Neutral  serine  proteases
such  as granulocyte elastase, cathepsin G and mast
cell  chymase  are  potent  secretagogues  for  airway
gland serous cells. Histamine also degranulates serous
cells, but is not such a potent secretagogue as these
proteases.21–23
The purpose of this study is to report the the effect
of SLPI on IgE-mediated histamine release from nasal
mucosa in vitro. Another objective was to examine
whether IgE-stimulation  of nasal mucosa  caused an
increase in SLPI secretion.
Materials and Methods
Nasal mucosa was obtained from 11 patients under-
going  conchotomi  of  the  inferior  turbinate  due  to
nasal  congestion.  They  were  otherwise  healthy
patients with no known atopic predisposition. After,
surgery the mucosa was immediately transported to
the laboratory in a sterile test tube. The mucosa from
each  patient  was  then  separated from  the  osseous
part and divided into five equally sized pieces with a
scalpel. Each piece was weighed and put into a sterile
test tube containing Earle’s M-199 salt, (GIBCO BRL,
Life Technology, T¨ aby, Sweden). To stimulate antigen
cross-linking of membrane bound IgE and histamine
release  we  used  anti-IgE  (DAKO,  Glostrup,  Den-
mark).10 RhSLPI  was  obtained  from  Synergen  Inc,
Boulder, CO, USA.
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The  tissue  samples  from  each  patients  were  pre-
incubated in 2ml of the medium for 15min at 37°C.
After preincubation a final  concentration of 0, 7.5,
150m M  rhSLPI  were  added  to  three  different  test
tubes and incubated for 15min at 37°C. Then 15m l
anti-IgE, 15g/l, were added to these three test tubes.
Inhibition  of  spontaneous  histamine  release  was
measured by incubating one tissue sample with the
final  concentration  of  150m M  rhSLPI  without  any
anti-IgE-stimulation.  One  test  tube  tissue  was  incu-
bated  with  medium  only.  Incubation  continued  at
37°C. Samples of 200m l were taken from each of the
five  test  tube  supernatants  before  (0min),  15min
after adding rhSLPI and then the following 30, 45, 75
and 135min.
Histamine release was measured with a commercial
radioimmunoassay  (RIA)-kit  (Immunotech,  KEMILA,
Sollentuna, Sweden). The RIA-kit was able to detect
non-methylated histamine. Briefly, the RIA was per-
formed  as  follows:  step  1,  acetylation  of  standard
solution or sample; step 2, 50m l acetylated standard
or sample and 500m l tracer was added into antibody
coated  tubes  and  were  then  incubated  for  18h  at
2–6°C; step 3, the coated tubes were aspirated and
the total counts per minutes and bound counts per
minutes  were  registered.  Histamine  release  was
expressed  as  the  percentage  increase  or  decrease
relative to the sample taken before anti-IgE-stimula-
tion and after incubation with rhSLPI.
Assay of SLPI
Tissue  samples  from  six  subjects  were  treated  as
previously described. They were preincubated in 2ml
Earle’s M-199 salt, for 15min at 37°C. A medium sample
of 200m l was removed from each test tube. One tissue
sample was incubated in medium only while the other
was  stimulated  with  anti-IgE. Then  200m l  medium
were collected from each test tube at 30, 45, 75 and
135min after anti-IgE stimulation. SLPI was measured
with non-competitive ELISA, as described earlier by
Bergenfeldt  and  Ohlsson.24 Monoclonal  mouse-anti-
bodies against SLPI (produced at our laboratory) were
made to adhere to wells of microtitre plates.
Diluted samples and standard were then added. An
anti-SLPI sheep IgG-antiserum (produced at our labo-
ratory)  was  then added. Finally,  a  rabbit  anti-sheep
IgG antibody, conjugated with alkaline phosphatase
(Dakopatt AS, Copenhagen, Denmark), was added.
Alkaline phosphatase cleaved the substrate (4-para-
nitro-phenyl-phosphate). The substrate was quantified
at 405nm in an automatic Titertec multiscan photo-
meter. To verify the effect of anti-IgE we measured the
histamine  release  as  described  above.  SLPI  was
expressed as the percentage increase compared with
the sample taken before stimulation with anti-IgE.
Statistics
Regression  coefficients  were  calculated  for  each
histamine release curve from each one of the experi-
ments. The hypothesis, i.e. the differences in regres-
sion coefficient  were  tested with  a  non-parametric
Wilcoxon’s paired rank sum test.25
The  Man–Whitney  U-test  was  calculated  on  the
results at 30, 45, 75 and 135min in order to see if
there was a significant increase in SLPI due to IgE-
stimulation.
Results
When  nasal  mucosa  from  11  subjects  were  pre-
incubated with SLPI, IgE-mediated histamine release
was inhibited in a dose-dependent manner. There was
significant inhibition (P = 0.028 and P = 0.015) of
histamine  release  at  SLPI  concentrations  of  7.5m M
and  150m M.  Inhibition  was  observed  after  30min
incubation  (Fig.  1).  RhSLPI  inhibited  IgE-mediated
histamine release to the level of spontaneous hista-
mine  release  (Fig.  2),  but  did not  affect  histamine
release in the absence of IgE stimulation (Fig. 3).
Pronounced  IgE-mediated  histamine  release  was
observed in the absence of added rhSLPI (P = 0.0093)
compared with spontaneous histamine release (Fig.
4).
The effect of IgE on nasal mucosal secretion of SLPI
was also studied (six subjects). No significant increase
in  SLPI  was  observed  when  nasal  mucosa  was
subjected to IgE stimulation in vitro.
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FIG. 1. IgE-mediated histamine release in nasal mucosa at
various  concentrations,  0m M  (–s –),  7.5m M  (–d –),  150m M
(–m –) SLPI. There was a significant inhibition (P= 0.028 and P
= 0.015) of histamine release at 7.5m M and 150m M. Statistics
are calculated on the regression coefficient from the results
of  the  11  subjects.  This  figure  shows  results  from  a
representative experiment.Discussion
Recent studies indicate that SLPI probably plays a role
as a regulator in IgE-mediated reactions, perhaps by
inhibiting chymase activity.12,13 Chymase is a serine
protease which resides in mast cell granules.16,26,27
Mast  cell  degranulation  is  most  likely  caused  by
chymase, thus inducing histamine release.15,17–19 We
have shown that SLPI inhibits IgE-mediated histamine
release  in  a  dose-dependent  manner  in  explanted
human nasal mucosa (Fig. 1). SLPI inhibits histamine
release to the level of spontaneous release (Fig. 2).
These results support the suggestion that SLPI may be
an  important  participant  in  allergic  reactions. The
findings of Dietze et al.12 suggest that preincubating
tonsilar mast cells with r-MPI (SLPI) for 30min had no
effect, while incubation for 120min restricted hista-
mine release to the level of spontaneous release. Their
study  indicated that  the inhibitor may not have  an
impact on immediate hypersensitive reactions, but is
of  greater  importance  to  prolonged  allergen  expo-
sure. By incubating human nasal mucosa with SLPI,
we found pronounced inhibition of histamine release
after 30min, supporting the importance of SLPI as a
regulator  in  immediate  hypersensitive  reactions.
Whether or not SLPI forms complexes with chymase
intra- or extracellularly is not known. Antibodies of
chymase are incorporated into mast cell granules and
inhibit histamine release, as shown by Kido et al.18
However, mast cells granules contain SLPI,28 which
may indicate that the inhibitor is able to penetrate the
cell membrane and act as a regulator inside the cell. It
has been shown that SLPI increases in nasal secretion
in  allergic  subjects  when  they  are  exposed  to
allergens.20 Serine  proteases  such  as  elastase,  cath-
epsin G and chymase are  potent secretagogues  for
airway  gland  serous  cells.21–24 We  proposed  that
chymase may also stimulate the secretion of SLPI. By
incubating  nasal  mucosa  with  anti-IgE,  mast  cell
chymase is activated and may be able to stimulate the
serous cells of nasal mucosa. No significant increase
in SLPI secretion could be seen, which may suggest
that  a  nervous  component  is  required  to  increase
secretion in response to this kind of stimulation. In
conclusion,  our  results  obtained  from  experiments
with intact human nasal mucosa, support the theories
that SLPI plays a role in type 1 reactions by inhibiting
histamine release, and that IgE does not affect SLPI
secretion in nasal mucosa ex vivo.
SLPI inhibits IgE-mediated histamine release
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FIG. 2. IgE-mediated histamine release in nasal mucosa at
various concentration, 7.5m M (–d –) and 150m M, (–m –) of SLPI
compared  with  spontaneously  released  histamine  (–h –).
SLPI had no influence on spontaneous histamine release.
FIG. 3. Spontaneously released histamine in nasal mucosa
incubated with SLPI, 150m M, (–h –) compared with sponta-
neously released histamine in the absence of SLPI (–j –). No
significant inhibition of histamine release was seen in the
absence of IgE-stimulation.
FIG. 4. Anti-IgE induced histamine release in nasal mucosa
(–s –) compared with spontaneous release (–j –). This figure
demonstrates the effect of IgE on histamine release in nasal
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